J
Jonathan D. Cheng
Researcher at Merck & Co.
Publications - 79
Citations - 14060
Jonathan D. Cheng is an academic researcher from Merck & Co.. The author has contributed to research in topics: Pembrolizumab & Head and neck squamous-cell carcinoma. The author has an hindex of 33, co-authored 77 publications receiving 9356 citations. Previous affiliations of Jonathan D. Cheng include Yonsei University.
Papers
More filters
Journal ArticleDOI
IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers,Jared Lunceford,Michael Nebozhyn,Erin Murphy,Andrey Loboda,David Ross Kaufman,Andrew Albright,Jonathan D. Cheng,S. Peter Kang,Veena Shankaran,Sarina Anne Piha-Paul,Jennifer H. Yearley,Tanguy Y. Seiwert,Antoni Ribas,Terrill K. McClanahan +14 more
TL;DR: The T cell–inflamed GEP contained IFN-&ggr;–responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit.
Journal ArticleDOI
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study
Barbara Burtness,Kevin J. Harrington,Richard Greil,Denis Soulières,Makoto Tahara,Gilberto de Castro,Amanda Psyrri,Neus Baste,Prakash Neupane,Åse Bratland,Thorsten Fuereder,Brett G.M. Hughes,Ricard Mesia,Nuttapong Ngamphaiboon,Tamara Rordorf,Wan Zamaniah Wan Ishak,Ruey-Long Hong,René González Mendoza,Ananya Roy,Yayan Zhang,Burak Gumuscu,Jonathan D. Cheng,Fan Jin,Danny Rischin,Danny Rischin,Guillermo Lerzo,Marcelo Tatangelo,Mirta Varela,J. J. Zarba,Michael Boyer,Hui K Gan,Bo Gao,Brett Hughes,Girish Mallesara,Anne W. Taylor,Martin Burian,Carlos H. Barrios,Dalvaro Oliveira de Castro Junior,Gilberto de Castro,Fabio Franke,Gustavo Girotto,Iane Pinto Figueiredo Lima,Ulisses Ribaldo Nicolau,Gustavo Dix Junqueira Pinto,Lucas Vieira dos Santos,Ana Paula Victorino,Neil Chua,Felix Couture,Richard Gregg,Aaron R. Hansen,John Hilton,Joy McCarthy,Rodrigo Ascui,Pablo Gonzalez,Luis Villanueva,Marco Torregroza,Angela Zambrano,Petra Holeckova,Zdenek Kral,Bohuslav Melichar,Jana Prausova,Milan Vosmik,Maria Andersen,Niels Gyldenkerne,Hannes Jurgens,Kadri Putnik,Petri Reinikainen,Viktor Gruenwald,Simon Laban,Gerasimos Aravantinos,Ioannis Boukovinas,Vassilis Georgoulias,Dora Kwong,Yousuf Al-Farhat,Tibor Csoszi,Jozsef Erfan,Geza Horvai,Laszlo Landherr,Éva Remenár,Agnes Ruzsa,Judit Szota,Salem Billan,Iris Gluck,Orit Gutfeld,Aron Popovtzer,Marco Benasso,Simona Bui,Vittorio Ferrari,Lisa Licitra,Franco Nolè,Takashi Fujii,Yasushi Fujimoto,Nobuhiro Hanai,Hiroki Hara,Koji Matsumoto,Kenji Mitsugi,Nobuya Monden,Masahiro Nakayama,Kenji Okami,Nobuhiko Oridate,Kiyoto Shiga,Yasushi Shimizu,Masashi Sugasawa,Masanobu Takahashi,Shunji Takahashi,Kaoru Tanaka,Tsutomu Ueda,Hironori Yamaguchi,Tomoko Yamazaki,Ryuji Yasumatsu,Tomoya Yokota,Tomokazu Yoshizaki,Iveta Kudaba,Zinaida Stara,Soon Keat Cheah,Jose Aguilar Ponce,Carlos Hernandez Hernandez,Francisco Medina Soto,Jan Buter,Ann Hoeben,Sjoukje F. Oosting,Karijn P M Suijkerbuijk,Aase Bratland,Marianne Brydoey,Renzo Alvarez,Luis Mas,Priscilla Caguioa,John Querol,Eugenio Emmanuel Regala,Maria Belen Tamayo,Ellie May Villegas,Andrzej Kawecki,Andrey Karpenko,Arkadiy Klochikhin,Alexey Smolin,Oleg Zarubenkov,Boon Cher Goh,Graham Cohen,Johanna du Toit,Christa Jordaan,Gregory Landers,Paul Ruff,Waldemar Szpak,Neonyana Tabane,Irene Brana,Lara Carmen Iglesias Docampo,Javier Lavernia,Edvard Abel,Valentina Muratidu,Niels Nielsen,Valerie Cristina,Sacha Rothschild,Hung Ming Wang,Muh Hwa Yang,Su Peng Yeh,Chia Jui Yen,Nopadol Soparattanapaisarn,Virote Sriuranpong,Sercan Aksoy,Irfan Cicin,Meltem Ekenel,Hakan Harputluoglu,Ozgur Ozyilkan,Kevin J. Harrington,Sanjiv S. Agarwala,Haythem Ali,Robert Alter,Daniel Anderson,Justine Bruce,Nicholas Campbell,Miguel Conde,John F. Deeken,William Edenfield,Lawrence E. Feldman,Elizabeth Gaughan,Basem Goueli,Balazs Halmos,Upendra P. Hegde,Brian Hunis,Robert Jotte,Anand B. Karnad,Saad A. Khan,Noel Laudi,Douglas Laux,Danko Martincic,Steven McCune,Dean McGaughey,Krzysztof Misiukiewicz,Deborah Mulford,Eric Nadler,Johannes Nunnink,James Ohr,Meaghan O'Malley,Brian Patson,Doru Paul,Elizabeta Popa,Steven Francis Powell,Rebecca Redman,Vincent Rella,Chaio Rocha Lima,Abirami Sivapiragasam,Yungpo Su,Ammar Sukari,Stuart Wong,Emrullah Yilmaz,Jeffrey Yorio +205 more
TL;DR: A randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries finds that pembrolizumab alone improved overall survival and progression-free survival and cetuximab with chemotherapy improved Overall survival in the total population.
Journal ArticleDOI
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Razvan Cristescu,Robin Mogg,Mark Ayers,Andrew Albright,Erin Murphy,Jennifer H. Yearley,Xinwei Sher,Xiaoqiao Liu,Hongchao Lu,Michael Nebozhyn,Chunsheng Zhang,Jared Lunceford,Andrew K. Joe,Jonathan D. Cheng,Andrea L. Webber,Nageatte Ibrahim,Elizabeth R. Plimack,Patrick A. Ott,Tanguy Y. Seiwert,Antoni Ribas,Terrill K. McClanahan,Joanne E. Tomassini,Andrey Loboda,David Ross Kaufman +23 more
TL;DR: The potential for TMB and a T cell–inflamed GEP to jointly predict clinical response to pembrolizumab was assessed in >300 patient samples with advanced solid tumors and melanoma across 22 tumor types from four KEYNOTE clinical trials.
Journal ArticleDOI
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert,Barbara Burtness,Ranee Mehra,Jared Weiss,Raanan Berger,Joseph Paul Eder,Karl Heath,Terrill K. McClanahan,Jared Lunceford,Christine K. Gause,Jonathan D. Cheng,Laura Qm Chow +11 more
TL;DR: Pembrolizumab was well tolerated and demonstrated clinically meaningful antitumour activity in recurrent or metastatic squamous cell carcinoma of the head and neck, supporting further study of pembrolIZumab as anticancer therapy for advancedHead and neck cancers.
Journal ArticleDOI
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda,Laura Q.M. Chow,Claire Dees,Raanan Berger,Shilpa Gupta,Ravit Geva,Lajos Pusztai,Kumudu Pathiraja,Gursel Aktan,Jonathan D. Cheng,Vassiliki Karantza,Laurence Buisseret +11 more
TL;DR: This phase Ib study describes preliminary evidence of clinical activity and a potentially acceptable safety profile of pembrolizumab given every 2 weeks to patients with heavily pretreated, advanced TNBC.